Program for Early Recovery and Resilience Building from EVD Outbreak in Liberia
Prepared by the Independent Panel for Pandemic Preparedness and Response for the WHO Executive Board, January 2021
“The world was not as prepared as it should have been, and it must do better,” concludes a WHO panel reviewing the pandemic response "
Vision 2030
Accessed: 17.11.2019
This publication describes the first WHO public-benefit Target Product Profiles (TPPs) for snakebite antivenoms. It focuses on antivenoms for treatment of snakebite envenoming in sub-Saharan Africa. Four TPPs are described in the document:
Broad spectrum Pan-African polyvalent antivenoms: products ...that are intended for widespread utility throughout sub-Saharan Africa for treatment of envenoming irrespective of the species of snake causing a bite. Monovalent antivenoms for specific use cases: for products for a single species (or genus) of snake (e.g., boomslangs or carpet viper antivenoms).
Syndromic Pan-African polyvalent antivenoms for neurotoxic envenoming: products that are intended for treatment of envenoming by species whose venoms are neurotoxic. Syndromic Pan-African polyvalent antivenoms for non-neurotoxic envenoming: products for snakebite envenoming where the effects are largely haemorrhagic, necrotic or procoagulant.
more
Revised National Tuberculosis Control Programme
Version: 2.0 Date: 19.3.2020
Operational Guidelines for Programme Managers & Service Providers
For each medicine the Formulary provides information on use, dosage, adverse effects, contraindications and warnings, supplemented by guidance on selecting the right medicine for a range of conditions
Psychiatry and Pediatrics
Chapter I.4
Copenhagen, Denmark, 24–25 August 2017
World Drug Report 2018
-3-